|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0230 AUD | +21.05% |
|
+35.29% | -4.17% |
| 02-27 | Nexalis Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 02-17 | Nexalis Therapeutics Limited will Change its Ticker to NX1 from IRX | CI |
| Capitalization | 5.82M 4.18M 3.54M 3.26M 3.09M 5.72M 387M 38.19M 14.97M 188M 15.69M 15.37M 661M | P/E ratio 2024 |
-6.17x | P/E ratio 2025 | -3.2x |
|---|---|---|---|---|---|
| Enterprise value | 6.12M 4.4M 3.73M 3.43M 3.25M 6.02M 407M 40.19M 15.76M 197M 16.51M 16.17M 696M | EV / Sales 2024 |
18.2x | EV / Sales 2025 | 6.13x |
| Free-Float |
36.31% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +21.05% | ||
| 1 week | +35.29% | ||
| Current month | +15.00% | ||
| 1 month | -4.17% | ||
| 3 months | +4.55% | ||
| 6 months | -30.30% | ||
| Current year | -4.17% |
| 1 week | 0.02 |  | 0.02 |
| 1 month | 0.02 | | 0.03 |
| Current year | 0.02 | | 0.03 |
| 1 year | 0.02 | | 0.05 |
| 3 years | 0.02 | | 0.05 |
| 5 years | 0.02 | | 0.13 |
| 10 years | 0.02 | | 0.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
Darryl Davies
CEO | Chief Executive Officer | - | 27/09/2022 |
Rob Jenny
CTO | Chief Tech/Sci/R&D Officer | - | 27/09/2022 |
James Barrie
SEC | Corporate Secretary | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Sean Williams
CHM | Chairman | - | 27/07/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +21.05% | +35.29% | +27.78% | -48.89% | 3.45M | |
| +2.22% | +5.51% | +0.78% | -7.93% | 47.35B | |
| +1.86% | +5.71% | +41.72% | +23.62% | 35.57B | |
| +0.66% | +55.55% | +308.05% | +510.50% | 31.16B | |
| +3.53% | +6.43% | +23.76% | -12.10% | 28.86B | |
| -0.72% | +2.98% | +35.64% | +28.89% | 29.62B | |
| +0.71% | +1.92% | +47.76% | +194.68% | 15.01B | |
| +0.54% | +5.84% | +76.30% | +167.16% | 14.73B | |
| -5.64% | +0.80% | +3,690.94% | +3,888.19% | 15.12B | |
| +0.87% | +8.85% | +40.89% | +13.56% | 14.34B | |
| Average | +2.38% | +9.20% | +429.36% | +475.77% | 23.18B | |
| Weighted average by Cap. | +0.69% | +11.27% | +306.71% | +350.50% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 402K 289K 245K 225K 213K 395K 26.73M 2.64M 1.03M 12.96M 1.08M 1.06M 45.66M | 986K 709K 601K 553K 523K 969K 65.61M 6.47M 2.54M 31.81M 2.66M 2.6M 112M |
| Net income | -1.21M -869K -736K -678K -641K -1.19M -80.44M -7.94M -3.11M -38.99M -3.26M -3.19M -137M | -1.62M -1.16M -986K -907K -858K -1.59M -108M -10.62M -4.17M -52.19M -4.37M -4.27M -184M |
| Net Debt | -161K -116K -97.95K -90.12K -85.29K -158K -10.7M -1.06M -414K -5.19M -434K -425K -18.28M | 304K 219K 185K 171K 161K 299K 20.25M 2M 783K 9.81M 821K 804K 34.59M |
Employees
-
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/04/26 | 0.0230 $ | +21.05% | 34,079 |
| 14/04/26 | 0.0190 $ | +5.56% | 19,673 |
| 13/04/26 | 0.0180 $ | 0.00% | 7,010 |
- Stock Market
- Equities
- NX1 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition